BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8573762)

  • 1. SH2 and SH3 domains: potential targets for anti-cancer drug design.
    Smithgall TE
    J Pharmacol Toxicol Methods; 1995 Nov; 34(3):125-32. PubMed ID: 8573762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem SH2 binding sites mediate the RasGAP-RhoGAP interaction: a conformational mechanism for SH3 domain regulation.
    Hu KQ; Settleman J
    EMBO J; 1997 Feb; 16(3):473-83. PubMed ID: 9034330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase signalling pathways.
    Pawson T
    Princess Takamatsu Symp; 1994; 24():303-22. PubMed ID: 8983084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SH2 and SH3-containing adaptor proteins: redundant or independent mediators of intracellular signal transduction.
    Birge RB; Knudsen BS; Besser D; Hanafusa H
    Genes Cells; 1996 Jul; 1(7):595-613. PubMed ID: 9078388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SH2 and SH3 domains as targets for anti-proliferative agents.
    Vidal M; Gigoux V; Garbay C
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):175-86. PubMed ID: 11682324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine phosphorylation of connexin 43 by v-Src is mediated by SH2 and SH3 domain interactions.
    Kanemitsu MY; Loo LW; Simon S; Lau AF; Eckhart W
    J Biol Chem; 1997 Sep; 272(36):22824-31. PubMed ID: 9278444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins.
    Koch CA; Anderson D; Moran MF; Ellis C; Pawson T
    Science; 1991 May; 252(5006):668-74. PubMed ID: 1708916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SH2/SH3 signaling proteins.
    Schlessinger J
    Curr Opin Genet Dev; 1994 Feb; 4(1):25-30. PubMed ID: 8193536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A specific intermolecular association between the regulatory domains of a Tec family kinase.
    Brazin KN; Fulton DB; Andreotti AH
    J Mol Biol; 2000 Sep; 302(3):607-23. PubMed ID: 10986122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
    Li S; Couvillon AD; Brasher BB; Van Etten RA
    EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteins with SH2 and SH3 domains couple receptor tyrosine kinases to intracellular signalling pathways.
    Pawson T; Olivier P; Rozakis-Adcock M; McGlade J; Henkemeyer M
    Philos Trans R Soc Lond B Biol Sci; 1993 Jun; 340(1293):279-85. PubMed ID: 8103930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The solution structure of Abl SH3, and its relationship to SH2 in the SH(32) construct.
    Gosser YQ; Zheng J; Overduin M; Mayer BJ; Cowburn D
    Structure; 1995 Oct; 3(10):1075-86. PubMed ID: 8590002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gads is a novel SH2 and SH3 domain-containing adaptor protein that binds to tyrosine-phosphorylated Shc.
    Liu SK; McGlade CJ
    Oncogene; 1998 Dec; 17(24):3073-82. PubMed ID: 9872323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation.
    Young MA; Gonfloni S; Superti-Furga G; Roux B; Kuriyan J
    Cell; 2001 Apr; 105(1):115-26. PubMed ID: 11301007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains.
    Chalupny NJ; Aruffo A; Esselstyn JM; Chan PY; Bajorath J; Blake J; Gilliland LK; Ledbetter JA; Tepper MA
    Eur J Immunol; 1995 Oct; 25(10):2978-84. PubMed ID: 7589101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation: new aspects.
    Fox JE
    Haemostasis; 1996 Oct; 26 Suppl 4():102-31. PubMed ID: 8979117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo.
    Lerner EC; Smithgall TE
    Nat Struct Biol; 2002 May; 9(5):365-9. PubMed ID: 11976726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proline isomerization preorganizes the Itk SH2 domain for binding to the Itk SH3 domain.
    Severin A; Joseph RE; Boyken S; Fulton DB; Andreotti AH
    J Mol Biol; 2009 Apr; 387(3):726-43. PubMed ID: 19361414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Src homology 2 domain of the protein-tyrosine kinase p56lck mediates both intermolecular and intramolecular interactions.
    Amrein KE; Panholzer B; Flint NA; Bannwarth W; Burn P
    Proc Natl Acad Sci U S A; 1993 Nov; 90(21):10285-9. PubMed ID: 7694287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.